Venus Remedies Ltd, a leading research based global pharmaceutical company, which is carrying out novel formulations research for oncology, neurology, cardiometabolic, pain management and infections, has over 80 patents for its innovative research products from across the world. Some of these latest development include the Vancoplus, ACHNIL, DPCC, Carbapenem, Trios and Elores.

The Venus Medicine Research Centre at Baddi in Himachal Pradesh has been the hub of the R&D activities. Each of the research activities have been has been recognized by either global regulators or with patents grants.

Vancoplus is a novel research product for bacterial resistance caused by Methicillin Resistant Staphylococcus Aureus ( MRSA ) strain under the super bug category for which it has received patents from Japan, Canada and Mexico.'ACHNIL' based on Novel Drug Delivery System technology is a once-a-day painkiller which won the BioSpectrum Asia Award.

The company established pre-clinical proof-of-concept for its Drug -Protein- Polymer- Conjugate (DPPC) which is a novel, patent protected technology,to help in alleviating cancer specific and selective targeting of tumour cells.

For a novel antibiotic combination of carbapenem and aminoglycoside, Venus received its first patent from Companies and Intellectual Property Registration Office ( CIPRO), South Africa.

It bagged a US patent for CSE1034 branded as Elores which is a breakthrough antibiotic adjuvant entity (AAE), found to be effective against drug resistant infections including the `super bugs’ like carbapenemase resistant Metallobetalactamses (MBL) strains.

It also has developed TROIS, a nano-emulsion by integrating natural medicine approach to relieve pain & inflammation associated with osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, gouty arthritis, ankylosing spondylitis, psoriatic arthritis, backache, sprain and fibromyalgia.

In December 2012, Drugs Controller General of India (DCGI) approved its cancer detection New Chemical Entity(NCE) VRP1620 for phase-III clinical trials. The Indian regulator has found clinical phase-I and phase II data satisfactory and consented for phase-III trials, said Pawan Chaudhary CMD, Venus Remedies Ltd.